Applied Genetic Technologies (AGTC) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020
February 11, 2021 7:00 AM EST- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022 -
- Net proceeds of approximately $69.2 million from a recent public offering provide cash runway into calendar year 2023 -
- Company to host conference call and webcast today at 8:00 a.m. ET -
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for... More
